We are transforming cancer treatment with first-in-class cell therapies, with enhanced and targeted potency, improved safety and broad applicability across hematologic and solid tumor cancers. Our lead NK cell therapies are designed to offer countless patients a powerful anti-cancer therapeutic option.
Acepodia’s first-in-class cell therapies consist of proprietary immune cell lines with enhanced cytotoxic properties that are supercharged with cancer targeting technologies to maximize anti-cancer activity directly against tumors. The company’s lead product candidate is ACE1702, an off-the-shelf antibody-conjugated natural killer cell therapy in clinical development for the treatment of HER2-expressing solid tumors.
oNK cells are a proprietary natural killer (NK) cell line that is derived from the 1-2% of NK cells that have enhanced cytotoxic properties through their over expression of activation receptors and very low expression of inhibitory receptors. oNK cells can be augmented using established and novel technologies to target and engage solid tumors and hematological malignancies.
Acepodia’s proprietary antibody cell-conjugation platform (ACC) uses live-cell compatible chemistry to attach tumor-targeting antibodies directly to the surface of immune cells to generate highly specific and potent cell therapies, without the need for genetic engineering. The ACC platform can significantly enhance the potency of immune cells, thereby addressing the current challenge of treating solid tumors with cellular therapy. Acepodia is utilizing its ACC technology with its oNK cells and gamma delta T cells.
Gamma delta (γδ) T cells have a unique T-cell receptor on their surface enabling them to participate in both adaptive and innate immune responses, but they represent only a small subset of T cells in peripheral blood. In addition to being inherently cytotoxic towards tumors, gamma delta T cells can recruit other immune cells to elicit a robust anti-cancer immune response. Acepodia is developing allogeneic gamma delta T cells for use in its cell therapy programs.
PROMISING PIPELINE OF CELL THERAPIES
ADVANCING THE NEXT GENERATION OF IMMUNOTHERAPY
Cancers 2021, 13(11), 2724 Hao-Kang Li, Ching-Wen Hsiao, Sen-Han Yang, Hsiu-Ping Yang, Tai-Sheng Wu, Chia-Yun Lee, Yan-Liang Lin, Janet Pan, Zih-Fei Cheng, Yan-Da Lai, Shih-Chia Hsiao and Sai-Wen Tang
San Francisco Business Times
CFO THOUGHT LEADER